Online citations, reference lists, and bibliographies.

Introduction To High-Density Lipoprotein, Dyslipidemia, And Coronary Heart Disease

E. Schaefer
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Alterations in plasma lipoproteins are major risk factors for coronary heart disease caused by atherosclerosis. The purpose of this chapter is to provide the reader with an overview of lipids, lipoprotein composition, lipoprotein metabolism, and lipoprotein disorders, with particular relevance to coronary heart disease risk (CHD). This chapter will then provide a framework for the reader to understand the remaining chapters in this book which have a primary focus on high-density lipoproteins (HDLs). This chapter will also allow the reader to rapidly move from a rudimentary view of lipids to a more thorough understanding of HDL, dyslipidemia, and CHD. Both increased low-density lipoprotein (LDL) cholesterol (>160 mg/dl or 4.2 mmol/l) and decreased HDL cholesterol ( 1,000 mg/dl or 11 mmol/l) can be associated with recurrent pancreatitis. In this chapter we cover lipoprotein composition, metabolism, and briefly review the rare lipoprotein disorders cerebrotendinous xanthomatosis, phytosterolemia, abetalipoproteinemia, hypobetalipoproteinemia, and lipoprotein lipase deficiency, as well as the more common disorders dysbetalipoproteinemia, dyslipidemia, combined hyperlipidemia, lipoprotein (a) excess, and familial hypercholesterolemia. Disorders of HDL metabolism are covered in other chapters in this book. The concluding chapter will summarize where we are with CHD risk assessment, lipid management, the current state of our knowledge about HDL metabolism, and therapies for the treatment of HDL deficiency.
This paper references
Molecular diagnosis of hypobetalipoproteinemia: an ENID review.
P. Tarugi (2007)
Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet.
S. Deeb (2003)
Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial
N. Matthan (2010)
Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans
T. Sudhop (2002)
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
S. Erqou (2009)
Alterations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHD[S]
N. Matthan (2009)
Hepatic lipase deficiency.
P. Connelly (1998)
Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1).
H. Davis (2008)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National
W. Taylor (2009)
Hypertriglyceridemia: phenomics and genomics
R. Hegele (2008)
Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism Published, JLR Papers in Press, May 27, 2007.
S. Lamon-Fava (2007)
Familial apolipoprotein E deficiency.
E. Schaefer (1986)
Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases
A. Ajees (2006)
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
S. Altmann (2004)
Apolipoprotein B gene mutations affecting cholesterol levels
Robert V Farese (1992)
Phytosterols and vascular disease.
S. John (2007)
Abetalipoproteinemia: two case reports and literature review
Rola Zamel (2008)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C. Baigent (2005)
Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease.
Zohar Keren (2009)
Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease
J. Genest (1992)
The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia.
D. Sprecher (1985)
Lipoproteins, nutrition, and heart disease.
E. Schaefer (2002)
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.
E. Ingelsson (2007)
Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial.
E. Schaefer (1994)
Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review.
Amit R Rahalkar (2009)
Dysbetalipoproteinaemia--clinical and pathophysiological features.
D. Blom (2002)
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
T. Pearson (2009)
Molecular genetics of the LDL receptor gene in familial hypercholesterolemia
H. Hobbs (1992)
Two novel mutations in the sterol 27‐hydroxylase gene causing cerebrotendinous xanthomatosis
S. Lamon-Fava (2002)
Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.
T. V. van Himbergen (2010)
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
R. Knopp (2008)
Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.
M. Shlipak (2000)
The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings.
J. Jenner (2005)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar